How to use nasal nitric oxide in a child with suspected primary ciliary dyskinesia by Simpson K & Brodlie M
Newcastle University ePrints - eprint.ncl.ac.uk 
Simpson K, Brodlie M.  
How to use nasal nitric oxide in a child with suspected primary ciliary 
dyskinesia.  
Archives of Disease in Childhood Education and Practice Edition 2017 
DOI: https://doi.org/10.1136/archdischild-2016-311468 
Copyright: 
© Article authors 2017. All rights reserved. No commercial use is permitted unless otherwise expressly 
granted. This article has been accepted for publication in Archives of Disease in Childhood Education and 
Practice Edition following peer Review. The definitive copyedited, typeset version Simpson K, Brodlie M. 
How to use nasal nitric oxide in a child with suspected primary ciliary dyskinesia. Archives of Disease in 
Childhood Education and Practice Edition 2017 is available online at: 
https://doi.org/10.1136/archdischild-2016-311468  
DOI link to article: 
https://doi.org/10.1136/archdischild-2016-311468 
Date deposited: 
02/06/2017 
HOW TO USE NASAL NITRIC OXIDE IN A CHILD WITH SUSPECTED PRIMARY 
CILIARY DYSKINESIA 
 
Kim Simpson1 and Malcolm Brodlie1,2* 
 
1Department of Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle 
upon Tyne, UK. 
2Institute of Cellular Medicine, Newcastle University, UK. 
 
*Corresponding author: Dr Malcolm Brodlie, MRC Clinician Scientist/Clinical Senior 
Lecturer and Honorary Consultant in Paediatric Respiratory Medicine, Level 3, Clinical 
Resource Building, Great North Children's Hospital, Royal Victoria Infirmary, Queen Victoria 
Road, Newcastle upon Tyne, NE1 4LP. UK. E-mail: malcolm.brodlie@ncl.ac.uk 
 
Word count: 1812 
 
Keywords: Respiratory, Primary Ciliary Dyskinesia, Screening, Nitric Oxide, Paediatrics 
 
 
 
 
ABSTRACT 
 
Measuring nasal nitric oxide (nNO) is increasingly used as part of testing for Primary Ciliary 
Dyskinesia (PCD). The diagnosis of PCD is often delayed until after bronchiectasis is 
established in the lungs and auditory damage has occurred. It is important that all 
paediatricians are aware of clinical features that are suggestive of PCD that should prompt 
diagnostic testing. nNO levels are recognised to be low in patients with PCD and results 
generated by static chemiluminescence analysers using velum closure technique in older 
children have good sensitivity and specificity. However to conclusively rule PCD in or out 
further tests of ciliary function are required and assessment of cilia ultrastructure, 
immunohistochemistry studies and genotyping may also be indicated. These tests are more 
complex, invasive and expensive than nNO. nNO is less well studied in younger children 
where tidal breathing measurements are required. Portable NO analysers are also 
increasingly used in practice. This paper discusses when to consider PCD as a possible 
diagnosis in a child along with the indications, physiological and technical background and 
clinical utility of nNO as a test for PCD in children. 
 
INTRODUCTION - WHAT IS PCD? 
 
Primary Ciliary Dyskinesia (PCD) refers to a varied group of genetic conditions caused by 
defective cilia function.[1] The specific defect in function, clinical phenotype and inheritance 
varies between different mutations. Motile cilia line the respiratory tract, ventricles of the 
brain and fallopian tubes and are responsible for the motility of spermatozoa. Normal cilia 
ultrastructure consists of 2 microtubules surrounded by 9 microtubules, known as the "9 plus 
2 arrangement". The outer microtubules have inner and outer dynein arms, which generate 
ciliary movement.  
 
In PCD cilia may be immobile, dyskinetic or aplastic.[2] There are already over 30 different 
mutations known to result in PCD, which is predominantly inherited in an autosomal 
recessive fashion.[3] Dysfunctional cilia cause reduced clearance of secretions in the 
respiratory tract and middle ear, problems with cerebrospinal fluid flow in the brain and 
defective transfer of sperm or ova for reproduction. Children with PCD are predisposed to 
recurrent lower respiratory tract infections, which often results in bronchiectasis and reduced 
lung function. Respiratory symptoms may appear early in life and there may be a history of 
unexplained neonatal respiratory distress. Other common clinical features include chronic 
rhinosinusitis and recurrent otitis media, causing conductive deafness, and reduced fertility.    
 
In the fetus motile cilia present on the embryonic node are involved in left-right chest and 
abdominal organ arrangement.[1, 3] Situs inversus is found in about half of people with 
PCD.[2] Kartagener’s syndrome is a triad of situs inversus, chronic sinusitis and 
bronchiectasis. Children with heterotaxic congenital heart disease, where there is isomerism 
of the atrial appendage and often other organ involevement as well, for example polysplenia 
or asplenia, should also be investigated for PCD.[4] The estimated prevalence of PCD is 1 in 
10 000, however this is recognised to be much higher in certain populations.[5] For example, 
a study found a prevalence of 1 in 2265 in a British Asian population and of these patients 
around half had consanguineous parents.[6]  
 
It is important that clinicians are aware of features (see Table 1) that are suggestive of a 
potential diagnosis of PCD in order that children can be promptly referred for diagnostic 
testing. PICADAR (PrImary CiliARy DyskinesiA Rule) is a recently developed tool to help 
identify children that should be referred for testing (see Table 3).[7] 
 
Table 1: When should I investigate a child for Primary Ciliary Dyskinesia? 
1. Several of the following: persistent wet cough, situs anomalies, congenital cardiac 
defects, persistent rhinitis, chronic middle ear disease with or without hearing loss, 
a term infant with neonatal upper and lower respiratory symptoms or neonatal 
intensive care admittance 
2. Patients with normal situs presenting with other features of Primary Ciliary 
Dyskinesia 
3. Siblings of children with Primary Ciliary Dyskinesia 
4. Symptoms of Primary Ciliary Dyskinesia and predictive tool such as PICADAR 
score >5 (see Table 3, possible scores range from 0 to 14, questions are based on 
birth and neonatal history and presence of situs abnormalities, congenital heart 
disease, perennial rhinitis and hearing or ear problems) 
 Adapted from Lucas et al. (2016).[8] 
 
 
DIAGNOSIS OF PCD 
 
The diagnosis of PCD is often delayed and children may unfortunately have established 
bronchiectasis and hearing impairment by the time of diagnosis.[2, 9, 10] It follows that early 
diagnosis is essential to implement specialist multidisciplinary follow up and appropriate 
treatment so that lung function and hearing can be preserved and quality of life improved as 
far as possible.[2] A recent European survey showed median age of diagnosis to be 5.8 
years in children with PCD and 3.5 years for those with PCD and situs inversus.[9] Children 
frequently attend several clinicians on multiple occasions before a diagnosis of PCD is 
established.[11]  
 
Children suspected of having PCD are usually assessed by tertiary respiratory 
paediatricians. Diagnosis is established by a combination of clinical history and tests 
including nasal nitric oxide (nNO), analysis of ciliary beat frequency and pattern by high-
speed video microscopy analysis (HSVA), transmission electron microscopy (TEM), 
genotyping and immunofluorescence.[1] Importantly, no single diagnostic test will identify all 
cases of PCD and there is no "gold standard" test as such. In November 2016 evidence-
based guidelines were published by the European Respiratory Society that include a 
diagnostic algorithm for the diagnosis of PCD.[8] The first step of the suggested algorithm 
involves nNO and use of HSVA where if both are normal further diagnostic tests can be 
avoided unless the clinical suspicion is very high.[8]  
 
 
USE OF NASAL NITRIC OXIDE 
 
HSVA and TEM demand specialist laboratory expertise and are time consuming and 
expensive. Importantly they also require either a nasal or tracheal brushing sample to 
harvest airway epithelial cells, which can be painful and distressing for the paediatric patient 
or may require a bronchoscopy under general anaesthesia.[1, 2] Furthermore, samples may 
be insufficient or ex vivo cell culture may be technically unsuccessful. Measuring nNO is 
both a less invasive and less technically demanding procedure.  
 NO is produced by enzymatic action of nitric oxide synthetases and biologically is a key 
signalling molecule involved in multiple processes; most notably causing smooth muscle 
relaxation and vasodilatation.[12] It is important to make the distinction between nNO, which 
is often expressed in terms of flow as nL/minute, and fractional exhaled (whole breath) NO 
that is commonly used as a biomarker of eosinophilic inflammation in asthma and reported 
as a concentration in parts per billion.[13, 14]   
 
Several studies have identified significantly low levels of nNO in patients with PCD 
compared with healthy volunteers and other respiratory disease comparators, most notably 
cystic fibrosis.[15-20] The exact mechanism by which nNO levels are low in PCD is currently 
unknown.[2, 19, 20] Divergent hypotheses have been proposed ranging from increased 
metabolism or reduced production of NO by airway epithelial cells in PCD to abnormalities in 
the paranasal sinuses leading to obstruction of NO or reduced production at this site.[20]  
 
nNO concentration is detected by sampling nasal gas. The "gold standard" method of 
measuring nNO concentration is by using a static chemiluminescence analyser.[1, 21] The 
patient is seated and a nasal sampling tube is placed into one nostril while air is entrained 
into the other nostril. The patient is then asked to hold their breath whilst performing a velum 
closure manoeuvre for 20 seconds.[21] Velum closure is when the patient exhales through 
their mouth against resistance. This ensures that the soft palate is closed and prevents any 
contamination from the pharynx.[21] The analyser displays nNO concentration in real time 
enabling a measurement from the peak plateau to be taken. A concentration in parts per 
billion is then converted to nL/minute to reflect the sampling rate. Medications the patient is 
taking are recorded, drugs such as nasal decongestents or steroids or antihistamines may 
alter nNO levels.[21] 
 The sensitivity and specificity of nNO as a test for PCD varies between different studies 
depending on the method of sampling, analyser used and age of the individual patients.[8, 
19] There is no universally agreed diagnostic threshold although 77nL/minute is most 
commonly used for children of school age and above using the velum closure technique.[19] 
The 2016 ERS guidelines conclude that sensitivity and specificity for diagnosing PCD by 
static chemiluminescence analyser measurements using velum closure technique in children 
over 6 years are favourable, at between 0.9-1 and 0.75-0.97 respectively.[8]     
 
Stationary chemiluminescent analysers are expensive and best suited to large tertiary 
centres. Portable electrochemical devices have also been developed, which are cheaper 
and easier to use. There is limited data comparing stationary and portable nNO devices but 
studies have shown them to be reliable in assessing nNO levels.[22, 23] Portable devices 
require the patient to hold their breath for longer and do not display the sampling in real time 
preventing sampling acceptability to be measured. 
 
An important further caveat is that in children under 6 years nNO measurement is 
particularly challenging and furthermore differences between children with PCD and healthy 
controls are less marked in the youngest age groups.[24] Pre-school children often struggle 
to perform velum closure manoeuvres therefore tidal breathing measurements have to be 
used that are less well validated and appear to be less accurate.[25]     
 
  
CLINICAL BOTTOM LINE 
All paediatricians should be aware of clinical features suggestive of PCD that should trigger 
referral for diagnostic assessment. nNO has good sensitivity and specificity when measured 
using a static analyser involving a velum closure manoeuvre in older children. It is also a 
fairly easy and inexpensive test to perform and does not require invasive sampling of 
epithelial cells from the nose or lower airway. Importantly the 2016 ERS guidelines do not 
consider the accuracy of nNO in isolation to be adequate to rule PCD out or in. The current 
clinical bottom line is such that even if nNO is normal children should undergo further testing 
if there is a strong clinical history. Table 2 summarises the advantages and disadvantages of 
nNO. A key area for further research and development in order to expand the utility of nNO 
in the diagnosis of PCD in younger children includes the validation of techniques and 
reference ranges for younger children - in whom there is arguably the greatest need to 
expedite and improve diagnostic techniques.      
 
Table 2. Advantages and disadvantages of nNO as a test for PCD in children 
Advantages Disadvantages 
May prevent invasive, complex and 
expensive ciliary investigations 
Velum closure difficult in young children 
Rapid test to perform Stationary chemiluminescence equipment 
can be expensive 
Standard protocols and good sensitivity and 
specificity in older children using velum 
closure technique (for example a cut-off level 
of 77 nL/minute in this context has been 
found to have 98% sensitivity) 
Small percentage of people with PCD have a 
normal nNO level, therefore false negatives 
are possible; equally if used inappropriately 
at a population screening level could lead to 
false positives and flooding of tertiary 
services. Current bottom line is that nNO is 
not considered accurate enough to rule PCD 
in or out in isolation where there is clinical 
suspicion. 
 Data on nNO levels and measurement 
techniques in children <6 years are limited 
 
 
  
CLINICAL VIGNETTES ILLUSTRATING INDICATIONS AND LIMITATIONS OF nNO 
TESTING 
  
1. What clinical history should make you consider screening for PCD in a child? 
PCD is suggested with early onset respiratory symptoms and any of: 
1. Situs inversus totalis or heterotaxic syndrome 
2. Neonatal nasal congestion and/or unexplained neonatal respiratory distress 
3. Positive family history of PCD 
4. Males with dysmotile sperm 
5. Persistent productive cough, bronchiectasis and severe upper airway disease after 
common causes excluded 
6. Early onset of the combination of both severe upper and lower respiratory tract 
infections 
7. Persistent or frequent serous otitis media (glue ear) associated with respiratory 
symptoms 
 
The ERS guidelines also suggest use of a recently developed predictive tool, PICADAR, see 
Table 3.[7, 8] This uses seven simple questions to predict the likelihood of a child having 
PCD. A score greater than 5 is considered significant, and has a sensitivity of 0.9 and 
specificity of 0.75, that should prompt referral for testing. 
 
Table 3. PrImary CiliAry DyskinesiA Rule (PICADAR tool)[7] 
Does the patient have a daily wet cough that started in 
early childhood? 
YES – complete PICADAR 
No – stop PICADAR is not 
designed for patients without 
a wet cough 
Was the patient born pre-term or term? Term                         2 
Did the patient experience chest symptoms in the Yes                           2 
neonatal period? 
Was the patient admitted to the neonatal unit? Yes                           2 
Does the patient have a situs abnormality? Yes                           4 
Does the patient have a congenital heart defect? Yes                           2 
Does the patient have persistent perennial rhinitis? Yes                           1 
Does the patient experience chronic ear or hearing 
symptoms? 
Yes                           1 
 
 
2. In a child presenting with recurrent otitis media, a chronic wet cough since birth 
and sinusitis: does a low nNO level rule in a diagnosis of PCD? 
nNO should only be considered a screening test for PCD. Given the clinical history the pre-
test probability of PCD is high, the child has a PICADAR score of 6, and therefore they have 
been appropriately screened and a diagnosis of PCD is highly likely. The nNO test does 
however, have limitations. Low nNO levels can also occur in cystic fibrosis, sinusitis, nasal 
polyps, nasal obstruction and during an acute respiratory tract infection.[1] Further testing, 
for example HSVA, is also indicated for a definitive diagnosis of PCD to be reached.[8] 
Conversely it is also worth noting that there have been rare cases of PCD reported where 
nNO levels are within the normal range, for example some people with PCD associated with 
RSPH1 mutations have been found to have nNO levels >77 nL/min.[26] Therefore false 
negative results are also possible. This reiterates that if nNO levels are normal despite a 
classical history, referral for diagnostic testing is warranted.[2]  
 
Collins et al. published model predictive values for nNO levels using 282 consecutive 
referrals to their PCD service.[27] Using a screening threshold of 77 nL/min to exclude PCD 
they found that their data produced a sensitivity of 93.6% (95% CI 78.6-99.2) and specificity 
of 84.1% (78.9-88.4) with a positive predictive value of 42% (30.2 -54.5) and negative 
predictive value of 99.1% (96.7 to 99.9).[27] This suggests that a screening threshold of 77 
nL/min is generally effective in excluding PCD (whilst being mindful of the aforementioned 
caveat of potential false negative results) but that targeted screening of children with a 
raised pre-test probability based on their clinical history is likely to be most useful and 
effective in order to avoid overwhelming specialist services with children with false positive 
screening results in the absence of classical symptoms.[27]  
 
In summary therefore the history and screening test in this clinical scenario is suggestive of 
PCD and the patient requires prompt referral to a tertiary paediatric respiratory service for 
diagnostic testing. 
 
 
3. In a neonate born at term with unexplained respiratory distress and areas of 
collapse on chest radiograph, who required admission to a neonatal unit: does a 
normal nNO level rule out a diagnosis of PCD? 
Given the clinical history of a neonate with unexplained respiratory distress there is a 
possibility of PCD if the child goes on to develop other classical problems. The use of nNO 
for screening of neonates and infants is associated with difficulties. The para-nasal sinuses 
are underdeveloped in infants and healthy infants have been found to have lower nNO 
levels.[19] Furthermore, neonates and infants are unable to perform velum closure. 
Threshold screening levels for PCD are unknown and sampling techniques are not well 
established in infants. Indeed nNO testing is not well validated in children under 6 years of 
age.[2] Different respiratory manoeuvres have been suggested for use by younger children 
to measure nNO including performing measurements during breath holding, humming or 
tidal breathing.[19] Nonetheless the European Respiratory Society guidelines advise as a 
weak recommendation to measure nNO during tidal breathing in children under 6 years of 
age as part of PCD diagnostic workup.[8]  
 4. Should all children be screened for PCD using nNO? 
nNO is of maximum value when used as a targeted test in patients who have an increased 
likelihood of having PCD, see Table 1 and the PICADAR tool in Table 3. nNO testing can 
produce false positive results and if nNO screening were to be used at a population level the 
number of children potentially referred on for further diagnostic PCD tests would cause 
unnecessary worry for families plus major expense and swamping of specialist testing 
services. At present nNO is not considered sufficiently accurate to rule PCD in or out 
definitively.  
 
MULTIPLE CHOICE QUESTIONS 
 
1. Which of the following statements are true? 
A. PCD is often diagnosed under 3 years of age 
B. Diagnostic testing for PCD is currently cheap and easy to perform 
C. Diagnostic testing for PCD always involves genetic testing 
D. If nNO and HSVA are normal the diagnosis of PCD is very unlikely 
E. Fractional exhaled nitric oxide is a screening test for PCD 
 
2. Which of the following clinical histories would warrant testing for PCD? 
A. A child with recurrent lower respiratory tract infections, grommets and history of 
unexplained neonatal respiratory distress 
B. A child with a chronic productive cough and steatorrhoea 
C. A child with dextrocardia 
D. A child with nocturnal cough and exercise-induced wheeze 
E. A child with recurrent upper respiratory tract infections, sinusitis and family history 
of PCD 
 
      3.  Which of the following statements are true? 
A. The recommended technique to perform nNO screening uses a velum closure 
respiratory technique 
B. Threshold screening values for nNO in infants are well established 
C. nNO measurement in older children using velum closure technique has good 
sensitivity and specificity for PCD 
D. Chemiluminescence analysis of nNO levels is possible using a portable machine 
E. Alternative potential respiratory manoeuvres for nNO screening in preschool 
children include tidal breathing, humming and breath holding 
 
4. Limitations of nNO screening for PCD include: 
A. Lower values of nNO can also occur in CF, sinusitis, nasal polyps, nasal 
obstruction and with an acute respiratory tract infection 
B. It is a screening test with poor sensitivity 
C. A negative test cannot rule out a diagnosis of PCD when clinical history is highly 
suggestive 
D. Some patients with PCD may have normal nNO levels 
E. It cannot be used accurately in children less than 5 years of age 
 
5. Further research regarding screening for PCD is needed to: 
A. Ascertain threshold screening values for PCD 
B. Standardise acceptable respiratory manoeuvres for pre-school children to perform 
nNO screening 
C. Establish reasons for low nNO levels in patients with PCD 
D. Ascertain threshold screening values for PCD in neonates and infants 
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